Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: A multicenter, prospective cohort study

Duk Woo Park, Young Hak Kim, Hae Geun Song, Jung Min Ahn, Won Jang Kim, Jong Young Lee, Soo Jin Kang, Seung Whan Lee, Cheol Whan Lee, Seong Wook Park, Sung Cheol Yun, Sung Ho Her, Seung Ho Hur, Jin Sik Park, Myeong Kon Kim, Yun Seok Choi, Hyun Sook Kim, Jang Hyun Cho, Sang Gon Lee, Yong Whi ParkMyung Ho Jeong, Bong Ki Lee, Nae Hee Lee, Do-Sun Lim, Junghan Yoon, Ki Bae Seung, Won Yong Shin, Seung-Woon Rha, Kee Sik Kim, Seung Jea Tahk, Byoung Eun Park, Taehoon Ahn, Joo Young Yang, Yong Seok Jeong, Jay Hyun Rhew, Seung Jung Park

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background-It remains unclear whether there are differences in the safety and efficacy outcomes between everolimuseluting stents (EES) and sirolimus-eluting stents (SES) in contemporary practice. Methods and Results-We prospectively enrolled 6166 consecutive patients who received EES (3081 patients) and SES (3085 patients) between April 2008 and June 2010, using data from the Interventional Cardiology Research In-Cooperation Society-Drug-Eluting Stents Registry. The primary end point was a composite of death, nonfatal myocardial infarction (MI), or target-vessel revascularization (TVR). At 2 years of follow-up, the 2 study groups did not differ significantly in crude risk of the primary end point (12.1% for EES versus 12.4% for SES; HR, 0.97; 95% CI, 0.84-1.12, P=0.66). After adjustment for differences in baseline risk factors, the adjusted risk for the primary end point remained similar for the 2 stent types (HR, 0.96; 95% CI, 0.82-1.12, P=0.60). There were also no differences between the stent groups in the adjusted risks of the individual component of death (HR, 0.93; 95% CI, 0.67-1.30, P=0.68), MI (HR, 0.97; 95% CI, 0.79-1.18, P=0.74), and TVR (HR, 1.10; 95% CI, 0.82-1.49, P=0.51). The adjusted risk of stent thrombosis also was similar (HR, 1.16; 95% CI, 0.47-2.84, P=0.75). Conclusions-In contemporary practice of percutaneous coronary intervention procedures, the unrestricted use of EES and SES showed similar rates of safety and efficacy outcomes with regard to death, MI, sent thrombosis, and TVR. Future longer-term follow-up is needed to better define the relative benefits of these drug-eluting stents.

Original languageEnglish
Pages (from-to)365-371
Number of pages7
JournalCirculation: Cardiovascular Interventions
Volume5
Issue number3
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Sirolimus
Stents
Cohort Studies
Prospective Studies
Drug-Eluting Stents
Myocardial Infarction
Thrombosis
Everolimus
Safety
Percutaneous Coronary Intervention
Cardiology
Registries

Keywords

  • Angioplasty
  • Coronary disease
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice : A multicenter, prospective cohort study. / Park, Duk Woo; Kim, Young Hak; Song, Hae Geun; Ahn, Jung Min; Kim, Won Jang; Lee, Jong Young; Kang, Soo Jin; Lee, Seung Whan; Lee, Cheol Whan; Park, Seong Wook; Yun, Sung Cheol; Her, Sung Ho; Hur, Seung Ho; Park, Jin Sik; Kim, Myeong Kon; Choi, Yun Seok; Kim, Hyun Sook; Cho, Jang Hyun; Lee, Sang Gon; Park, Yong Whi; Jeong, Myung Ho; Lee, Bong Ki; Lee, Nae Hee; Lim, Do-Sun; Yoon, Junghan; Seung, Ki Bae; Shin, Won Yong; Rha, Seung-Woon; Kim, Kee Sik; Tahk, Seung Jea; Park, Byoung Eun; Ahn, Taehoon; Yang, Joo Young; Jeong, Yong Seok; Rhew, Jay Hyun; Park, Seung Jung.

In: Circulation: Cardiovascular Interventions, Vol. 5, No. 3, 01.06.2012, p. 365-371.

Research output: Contribution to journalArticle

Park, DW, Kim, YH, Song, HG, Ahn, JM, Kim, WJ, Lee, JY, Kang, SJ, Lee, SW, Lee, CW, Park, SW, Yun, SC, Her, SH, Hur, SH, Park, JS, Kim, MK, Choi, YS, Kim, HS, Cho, JH, Lee, SG, Park, YW, Jeong, MH, Lee, BK, Lee, NH, Lim, D-S, Yoon, J, Seung, KB, Shin, WY, Rha, S-W, Kim, KS, Tahk, SJ, Park, BE, Ahn, T, Yang, JY, Jeong, YS, Rhew, JH & Park, SJ 2012, 'Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: A multicenter, prospective cohort study', Circulation: Cardiovascular Interventions, vol. 5, no. 3, pp. 365-371. https://doi.org/10.1161/CIRCINTERVENTIONS.111.966549
Park, Duk Woo ; Kim, Young Hak ; Song, Hae Geun ; Ahn, Jung Min ; Kim, Won Jang ; Lee, Jong Young ; Kang, Soo Jin ; Lee, Seung Whan ; Lee, Cheol Whan ; Park, Seong Wook ; Yun, Sung Cheol ; Her, Sung Ho ; Hur, Seung Ho ; Park, Jin Sik ; Kim, Myeong Kon ; Choi, Yun Seok ; Kim, Hyun Sook ; Cho, Jang Hyun ; Lee, Sang Gon ; Park, Yong Whi ; Jeong, Myung Ho ; Lee, Bong Ki ; Lee, Nae Hee ; Lim, Do-Sun ; Yoon, Junghan ; Seung, Ki Bae ; Shin, Won Yong ; Rha, Seung-Woon ; Kim, Kee Sik ; Tahk, Seung Jea ; Park, Byoung Eun ; Ahn, Taehoon ; Yang, Joo Young ; Jeong, Yong Seok ; Rhew, Jay Hyun ; Park, Seung Jung. / Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice : A multicenter, prospective cohort study. In: Circulation: Cardiovascular Interventions. 2012 ; Vol. 5, No. 3. pp. 365-371.
@article{0fca8c06e5bb4df8b5e7099bb4d5d9ca,
title = "Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: A multicenter, prospective cohort study",
abstract = "Background-It remains unclear whether there are differences in the safety and efficacy outcomes between everolimuseluting stents (EES) and sirolimus-eluting stents (SES) in contemporary practice. Methods and Results-We prospectively enrolled 6166 consecutive patients who received EES (3081 patients) and SES (3085 patients) between April 2008 and June 2010, using data from the Interventional Cardiology Research In-Cooperation Society-Drug-Eluting Stents Registry. The primary end point was a composite of death, nonfatal myocardial infarction (MI), or target-vessel revascularization (TVR). At 2 years of follow-up, the 2 study groups did not differ significantly in crude risk of the primary end point (12.1{\%} for EES versus 12.4{\%} for SES; HR, 0.97; 95{\%} CI, 0.84-1.12, P=0.66). After adjustment for differences in baseline risk factors, the adjusted risk for the primary end point remained similar for the 2 stent types (HR, 0.96; 95{\%} CI, 0.82-1.12, P=0.60). There were also no differences between the stent groups in the adjusted risks of the individual component of death (HR, 0.93; 95{\%} CI, 0.67-1.30, P=0.68), MI (HR, 0.97; 95{\%} CI, 0.79-1.18, P=0.74), and TVR (HR, 1.10; 95{\%} CI, 0.82-1.49, P=0.51). The adjusted risk of stent thrombosis also was similar (HR, 1.16; 95{\%} CI, 0.47-2.84, P=0.75). Conclusions-In contemporary practice of percutaneous coronary intervention procedures, the unrestricted use of EES and SES showed similar rates of safety and efficacy outcomes with regard to death, MI, sent thrombosis, and TVR. Future longer-term follow-up is needed to better define the relative benefits of these drug-eluting stents.",
keywords = "Angioplasty, Coronary disease, Stents",
author = "Park, {Duk Woo} and Kim, {Young Hak} and Song, {Hae Geun} and Ahn, {Jung Min} and Kim, {Won Jang} and Lee, {Jong Young} and Kang, {Soo Jin} and Lee, {Seung Whan} and Lee, {Cheol Whan} and Park, {Seong Wook} and Yun, {Sung Cheol} and Her, {Sung Ho} and Hur, {Seung Ho} and Park, {Jin Sik} and Kim, {Myeong Kon} and Choi, {Yun Seok} and Kim, {Hyun Sook} and Cho, {Jang Hyun} and Lee, {Sang Gon} and Park, {Yong Whi} and Jeong, {Myung Ho} and Lee, {Bong Ki} and Lee, {Nae Hee} and Do-Sun Lim and Junghan Yoon and Seung, {Ki Bae} and Shin, {Won Yong} and Seung-Woon Rha and Kim, {Kee Sik} and Tahk, {Seung Jea} and Park, {Byoung Eun} and Taehoon Ahn and Yang, {Joo Young} and Jeong, {Yong Seok} and Rhew, {Jay Hyun} and Park, {Seung Jung}",
year = "2012",
month = "6",
day = "1",
doi = "10.1161/CIRCINTERVENTIONS.111.966549",
language = "English",
volume = "5",
pages = "365--371",
journal = "Circulation: Cardiovascular Interventions",
issn = "1941-7640",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice

T2 - A multicenter, prospective cohort study

AU - Park, Duk Woo

AU - Kim, Young Hak

AU - Song, Hae Geun

AU - Ahn, Jung Min

AU - Kim, Won Jang

AU - Lee, Jong Young

AU - Kang, Soo Jin

AU - Lee, Seung Whan

AU - Lee, Cheol Whan

AU - Park, Seong Wook

AU - Yun, Sung Cheol

AU - Her, Sung Ho

AU - Hur, Seung Ho

AU - Park, Jin Sik

AU - Kim, Myeong Kon

AU - Choi, Yun Seok

AU - Kim, Hyun Sook

AU - Cho, Jang Hyun

AU - Lee, Sang Gon

AU - Park, Yong Whi

AU - Jeong, Myung Ho

AU - Lee, Bong Ki

AU - Lee, Nae Hee

AU - Lim, Do-Sun

AU - Yoon, Junghan

AU - Seung, Ki Bae

AU - Shin, Won Yong

AU - Rha, Seung-Woon

AU - Kim, Kee Sik

AU - Tahk, Seung Jea

AU - Park, Byoung Eun

AU - Ahn, Taehoon

AU - Yang, Joo Young

AU - Jeong, Yong Seok

AU - Rhew, Jay Hyun

AU - Park, Seung Jung

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background-It remains unclear whether there are differences in the safety and efficacy outcomes between everolimuseluting stents (EES) and sirolimus-eluting stents (SES) in contemporary practice. Methods and Results-We prospectively enrolled 6166 consecutive patients who received EES (3081 patients) and SES (3085 patients) between April 2008 and June 2010, using data from the Interventional Cardiology Research In-Cooperation Society-Drug-Eluting Stents Registry. The primary end point was a composite of death, nonfatal myocardial infarction (MI), or target-vessel revascularization (TVR). At 2 years of follow-up, the 2 study groups did not differ significantly in crude risk of the primary end point (12.1% for EES versus 12.4% for SES; HR, 0.97; 95% CI, 0.84-1.12, P=0.66). After adjustment for differences in baseline risk factors, the adjusted risk for the primary end point remained similar for the 2 stent types (HR, 0.96; 95% CI, 0.82-1.12, P=0.60). There were also no differences between the stent groups in the adjusted risks of the individual component of death (HR, 0.93; 95% CI, 0.67-1.30, P=0.68), MI (HR, 0.97; 95% CI, 0.79-1.18, P=0.74), and TVR (HR, 1.10; 95% CI, 0.82-1.49, P=0.51). The adjusted risk of stent thrombosis also was similar (HR, 1.16; 95% CI, 0.47-2.84, P=0.75). Conclusions-In contemporary practice of percutaneous coronary intervention procedures, the unrestricted use of EES and SES showed similar rates of safety and efficacy outcomes with regard to death, MI, sent thrombosis, and TVR. Future longer-term follow-up is needed to better define the relative benefits of these drug-eluting stents.

AB - Background-It remains unclear whether there are differences in the safety and efficacy outcomes between everolimuseluting stents (EES) and sirolimus-eluting stents (SES) in contemporary practice. Methods and Results-We prospectively enrolled 6166 consecutive patients who received EES (3081 patients) and SES (3085 patients) between April 2008 and June 2010, using data from the Interventional Cardiology Research In-Cooperation Society-Drug-Eluting Stents Registry. The primary end point was a composite of death, nonfatal myocardial infarction (MI), or target-vessel revascularization (TVR). At 2 years of follow-up, the 2 study groups did not differ significantly in crude risk of the primary end point (12.1% for EES versus 12.4% for SES; HR, 0.97; 95% CI, 0.84-1.12, P=0.66). After adjustment for differences in baseline risk factors, the adjusted risk for the primary end point remained similar for the 2 stent types (HR, 0.96; 95% CI, 0.82-1.12, P=0.60). There were also no differences between the stent groups in the adjusted risks of the individual component of death (HR, 0.93; 95% CI, 0.67-1.30, P=0.68), MI (HR, 0.97; 95% CI, 0.79-1.18, P=0.74), and TVR (HR, 1.10; 95% CI, 0.82-1.49, P=0.51). The adjusted risk of stent thrombosis also was similar (HR, 1.16; 95% CI, 0.47-2.84, P=0.75). Conclusions-In contemporary practice of percutaneous coronary intervention procedures, the unrestricted use of EES and SES showed similar rates of safety and efficacy outcomes with regard to death, MI, sent thrombosis, and TVR. Future longer-term follow-up is needed to better define the relative benefits of these drug-eluting stents.

KW - Angioplasty

KW - Coronary disease

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=84864590466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864590466&partnerID=8YFLogxK

U2 - 10.1161/CIRCINTERVENTIONS.111.966549

DO - 10.1161/CIRCINTERVENTIONS.111.966549

M3 - Article

C2 - 22693347

AN - SCOPUS:84864590466

VL - 5

SP - 365

EP - 371

JO - Circulation: Cardiovascular Interventions

JF - Circulation: Cardiovascular Interventions

SN - 1941-7640

IS - 3

ER -